LEXINGTON, Mass., Nov. 11, 2019 /PRNewswire/ -- Agenus Inc.
(NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of
immune checkpoint antibodies, adoptive cell therapies1
and cancer vaccines, announced today that it received $10M
upfront for a License Agreement with UroGen Pharma Ltd. Under the
agreement Agenus is providing access to zalifrelimab (AGEN1884,
anti-CTLA-4 antibody) for use with UroGen's sustained release
technology for intravesical delivery in patients with urinary tract
cancers. Agenus is conducting clinical trials for
zalifrelimab in combination with Agenus' anti-PD-1 antibody
balstilimab (AGEN2034) for a planned BLA filing in cervical cancer.
In addition, zalifrelimab is being evaluated as a monotherapy in
PD-1 refractory patients.
Under the terms of the agreement, in addition to the
$10 million upfront payment, Agenus
is eligible to receive up to $200M in
potential development, regulatory and commercial milestones, as
well as 14-20% royalties on net sales.
"In our ongoing clinical trials, zalifrelimab and the
combination of zalifrelimab plus balstilimab (AGEN2034, anti-PD-1
antibody) have delivered durable as well as curative responses in
patients across a broad range of tumors. Agenus is developing
the combination in multiple solid tumors with a first planned BLA
filing in 2020," said Garo H. Armen, Ph.D., Chairman and CEO
of Agenus. "We are enthusiastic to expand the benefit of
zalifrelimab through intravesical delivery to patients with urinary
tract cancer in this exciting collaboration with UroGen."
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on
the discovery and development of therapies that engage the body's
immune system to fight cancer. The Company's vision is to expand
the patient populations benefiting from cancer immunotherapy with
combination approaches that leverage a broad repertoire of antibody
therapeutics, adoptive cell therapies (through its AgenTus
Therapeutics subsidiary) and its proprietary cancer vaccine
platforms. Agenus has a suite of antibody discovery platforms and a
state-of-the-art GMP manufacturing facility with the capacity to
support early phase clinical programs. Agenus is headquartered in
Lexington, MA. For more
information, please visit www.agenusbio.com and our twitter handle
@agenus_bio. Information that may be important to investors will be
routinely posted on our website and twitter.
Forward-Looking Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding Agenus' clinical
development and regulatory plans and timelines and the anticipated
benefits of the UroGen collaboration. These forward-looking
statements are subject to risks and uncertainties that could cause
actual results to differ materially. These risks and uncertainties
include, among others, the factors described under the Risk Factors
section of our most recent Quarterly Report on Form 10-Q or Annual
Report on Form 10-K filed with the Securities and Exchange
Commission. Agenus cautions investors not to place considerable
reliance on the forward-looking statements contained in this
release. These statements speak only as of the date of this press
release, and Agenus undertakes no obligation to update or revise
the statements, other than to the extent required by law. All
forward-looking statements are expressly qualified in their
entirety by this cautionary statement.
Contact:
Agenus Inc.
Jennifer Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com
1Through AgenTus Therapeutics, a subsidiary of
Agenus
View original
content:http://www.prnewswire.com/news-releases/agenus-receives-10m-from-urogen-pharma-for-rights-to-zalifrelimab-ctla-4-for-intravesical-treatment-of-urinary-tract-cancers-300955231.html
SOURCE Agenus Inc.